Sitemap - 2026 - The Microdose

Researchers ask probing questions about methylone study, and the complications of psychedelics access under the Right To Try Act

Can psilocybin alleviate phantom limb pain? 5 questions with neuroscientist Fadel Zeidan

What might the FDA Commissioner’s resignation mean for psychedelics? Ketamine infusions rapidly reduce suicidal and depressive symptoms during major depressive episodes

Do psychedelics lead to major life changes? 5 Questions with health behaviorist Nic Carlisle

Psilocybin changes people’s brains after their first trip; Anthropologists share first evidence of traditional psilocybin use outside of the Americas

Do psychedelics create a shared reality? 5 Questions with health psychologist Talea Cornelius

FDA issues priority vouchers for psychedelics developers Compass Pathways, Usona Institute, and Transcend Therapeutics

What do police think about psychedelic therapy? 5 Questions for psychologist Alexandra Hopkins

Trump’s psychedelics executive order and how Texas inspired (and may benefit from) it

Can an LLM get high? 5 Questions with clinical neuroscientist Ziv Ben-Zion

Scientists test if ketamine has antidepressant effects under anesthesia; France is the first to approve IV ketamine for severe suicidal crisis

Can you kill a bad trip?: 5 Questions for emergency physician Gregory Yates

Scientists engineered plants to produce five psychedelics at once; ‘Mega-analysis’ shows brain responses to five psychedelics share a “signature”

Two psilocybin bills progress in Massachusetts and Washington’s King County passes deprioritization proposal; New Mexico psilocybin program proposes new rules

Project Mind Control: 5 Questions with historian John Lisle

New analysis: Psychedelics may be no better than SSRIs in treating depression, Kentucky ibogaine bill and New Mexico psilocybin equity fund

Dolphins, LSD, and floating tanks : 5 Questions for filmmaker Courtney Stephens

Psilocybin seems to help tobacco smokers quit; Scientists discover a new species of psychedelic mushroom in Africa

Will the FDA ever fast-track psychedelic drugs? 5 Questions with drug regulation expert Daniel Eisenkraft Klein

AtaiBeckley’s MDMA product could treat social anxiety; HHS Secretary Kennedy talks psychedelics on Rogan podcast; WV Senate and SD legislature pass Compass trigger bills

Minds Before Brains

The FDA is changing the drug approval process; In a Senate hearing, Surgeon General nominee Casey Means was asked about psychedelics use

What should you listen to while tripping?: 5 Questions with auditory neuroscientist Nikolas Francis

Compass announces promising yet modest results from second Phase 3 psilocybin trial; Missouri hearings on ibogaine and psilocybin bills, New Hampshire psilocybin bill advances

A bonanza of new state psychedelics bills, including ones to fund ibogaine research and new trigger laws for synthetic psilocybin

Dreaming While Under: 5 Questions with anesthesiologist Harrison Shong-Wen Chow

Legislative updates in Mississippi, West Virginia, Oregon, and New Hampshire; Fast-tracked federal approval of Compass's synthetic psilocybin was vetoed; Federal bill proposes VA study psychedelics

Psychedelic narcissism: 5 Questions for psychotherapy researcher Henrik Jungaberle

Ibogaine consortium gains steam with new bills in MS and OK; Federal psychedelics efforts remain stagnant

The Untold Story of Women Psychedelic Therapists: 5 Questions with historian Zoë Dubus

RAND estimates millions of Americans microdosed psychedelics in 2025; New Jersey to commit $6 million to psilocybin research; new bills in New Hampshire and Iowa

New psychedelic legislative efforts in WA; NJ bill passes; MindMed and Cybin rebranding

Psychedelic Mad Men: 5 Questions for public health researcher Olivia Marcus

Compass Pathways partnering with national mental health clinic chain; Government lifts clinical hold on synthetic 5-MeO-DMT; and DEA ups drug quotas for psilocybin, psilocin, and DMT research

Healing From Healing: 5 Questions for medical anthropologist Adam Aronovich

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts